Recurrent hepatitis C after liver transplantation

Research output: Contribution to journalArticlepeer-review


Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients (

Original languageEnglish (US)
Pages (from-to)34-40
Number of pages7
JournalAnti-Infective Agents
Issue number1
StatePublished - Jan 1 2012
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Infectious Diseases


Dive into the research topics of 'Recurrent hepatitis C after liver transplantation'. Together they form a unique fingerprint.

Cite this